The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Open accessAbstract
BACKGROUND: Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. METHODS: We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracycline, taxane, or both) to receive standard postsurgical treatment either with capecitabine or without (control). The primary end point was disease-free survival. Secondary end points included overall survival. RESULTS: The result of the prespecified interim analysis met the primary end point, so this trial was terminated early. The final analysis showed that disease-free survival was longer in the capecitabine group than in the control group (74.1% vs. 67.6% of the patients were alive and free from recurrence or second cancer at 5 years; hazard ratio for recurrence, second cancer, or death, 0.70; 95% confidence interval [CI], 0.53 to 0.92; P=0.01). Overall survival was longer in the capecitabine group than in the control group (89.2% vs. 83.6% of the patients were alive at 5 years; hazard ratio for death, 0.59; 95% CI, 0.39 to 0.90; P=0.01). Among patients with triple-negative disease, the rate of disease-free survival was 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87), and the overall survival rate was 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90). The hand-foot syndrome, the most common adverse reaction to capecitabine, occurred in 73.4% of the patients in the capecitabine group. CONCLUSIONS: After standard neoadjuvant chemotherapy containing anthracycline, taxane, or both, the addition of adjuvant capecitabine therapy was safe and effective in prolonging disease-free survival and overall survival among patients with HER2-negative breast cancer who had residual invasive disease on pathological testing. (Funded by the Advanced Clinical Research Organization and the Japan Breast Cancer Research Group; CREATE-X UMIN Clinical Trials Registry number, UMIN000000843 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, F., Baselga, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv221 · Cited by 1,827
Self-citationBang, Y.-J., Kim, Y.-W., Yang, H.-K., Chung, H. C., Park, Y.-K., Lee, K. H., Lee, K.-W., Kim, Y. H., Noh, S.-I., Cho, J. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61873-4 · Cited by 1,705
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Noh, S. H., Park, S. R., Yang, H.-K., Chung, H. C., Chung, I.-J., Kim, S.-W., Kim, H.-H., Choi, J.-H., Kim, H.-K., Yu, W., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70473-5 · Cited by 1,049
Self-citationBear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer
Blum, J. L., Jones, S. E., Buzdar, A. U., LoRusso, P. M., Kuter, I., Vogel, C., Osterwalder, B., Burger, H.-U., Brown, C. S., & Griffin, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.485 · Cited by 783
Cited by
Breast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Breast cancer statistics, 2019
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,114
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,286
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Self-citationAnand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs
Bianchini, G., De Angelis, C., Licata, L., & Gianni, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00565-2 · Cited by 1,382
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Self-citationMittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., Iwata, H., Telli, M. L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31953-x · Cited by 1,083
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,040
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.016 · Cited by 1,008
Self-citationBreast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Burstein, H. J., Chew, H., Dang, C., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0030 · Cited by 951
Spring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., Smith, B. L., Alexander, B., Moy, B., Isakoff, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3492 · Cited by 938
Triple negative breast cancer: Pitfalls and progress
Zagami, P., & Carey, L. A. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00468-0 · Cited by 839
Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., Gnant, M., Aebi, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.06.023 · Cited by 821
Self-citationBurstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., Piccart-Gebhart, M., Regan, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz235 · Cited by 667
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Dent, R., McArthur, H., Pusztai, L., Kümmel, S., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2409932 · Cited by 561
Self-citationAdvances in systemic therapies for triple negative breast cancer
Leon-Ferre, R. A., & Goetz, M. P. (2023) · BMJ · doi:10.1136/bmj-2022-071674 · Cited by 507
Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.159 · Cited by 478
Self-citationCirculating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
Magbanua, M. J. M., Swigart, L. B., Wu, H.-T., Hirst, G. L., Yau, C., Wolf, D. M., Tin, A., Salari, R., Shchegrova, S., Pawar, H., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.007 · Cited by 462
Yau, C., Osdoit, M., van der Noordaa, M., Shad, S., Wei, J., de Croze, D., Hamy, A.-S., Laé, M., Reyal, F., Sonke, G. S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00589-1 · Cited by 456
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 433
Self-citationBreast cancer: an up‐to‐date review and future perspectives
Hong, R., & Xu, B. (2022) · Cancer Communications · doi:10.1002/cac2.12358 · Cited by 407
Immunotherapy in breast cancer: an overview of current strategies and perspectives
Debien, V., De Caluwé, A., Wang, X., Piccart-Gebhart, M., Tuohy, V. K., Romano, E., & Buisseret, L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00508-3 · Cited by 368
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Advances in the Systemic Treatment of Triple-Negative Breast Cancer
Lebert, J. M., Lester, R., Powell, E., Seal, M., & McCarthy, J. (2018) · Current Oncology · doi:10.3747/co.25.3954 · Cited by 330
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S.-B., Bear, H., McCarthy, N., Melé Olivé, M., Gelmon, K., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03639 · Cited by 326
Self-citationAdjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Kerr, A. J., Dodwell, D., McGale, P., Holt, F., Duane, F., Mannu, G., Darby, S. C., & Taylor, C. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102375 · Cited by 307
Biganzoli, L., Battisti, N. M. L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I. H., Cardoso, M.-J., Cheung, K.-L., de Glas, N. A., Trimboli, R. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30741-5 · Cited by 298
Progress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Johnson, K. S., Conant, E. F., & Soo, M. S. (2021) · Journal of Breast Imaging · doi:10.1093/jbi/wbaa110 · Cited by 280
El Bairi, K., Haynes, H. R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J. R., Sur, D., Amendola, L. C., Gharib, M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00346-1 · Cited by 268
Self-citationSo, J. Y., Ohm, J., Lipkowitz, S., & Yang, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108253 · Cited by 256
ESO–ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4)
Paluch-Shimon, S., Cardoso, F., Partridge, A. H., Abulkhair, O., Azim, H. A., Bianchi-Micheli, G., Cardoso, M.-J., Curigliano, G., Gelmon, K. A., Harbeck, N., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.284 · Cited by 254
Conforti, F., Pala, L., Sala, I., Oriecuia, C., De Pas, T., Specchia, C., Graffeo, R., Pagan, E., Queirolo, P., Pennacchioli, E., et al. (2021) · BMJ · doi:10.1136/bmj-2021-066381 · Cited by 170
Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1110 · Cited by 105
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Abraham, J. E., Pinilla, K., Dayimu, A., Grybowicz, L., Demiris, N., Harvey, C., Drewett, L. M., Lucey, R., Fulton, A., Roberts, A. N., et al. (2024) · Nature · doi:10.1038/s41586-024-07384-2 · Cited by 53
“The CREATE-X trial demonstrated a significant benefit in patients with TNBC from 6 months of adjuvant capecitabine given after neoadjuvant chemotherapy that left residual disease 25 .”
Skarping, I., Larsson, M., & Förnvik, D. (2022) · European Radiology · doi:10.1007/s00330-021-08306-w · Cited by 44
Yamauchi, H., Toi, M., Takayama, S., Nakamura, S., Takano, T., Cui, K., Campbell, C., De Vos, L., Geyer, C., & Tutt, A. (2023) · Breast Cancer · doi:10.1007/s12282-023-01451-8 · Cited by 13
Self-citation
Metadata
- Authors
- Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., Yanagita, Y., Ohno, S., Takao, S., Aogi, K., Iwata, H., Jeong, J., Kim, A., Park, K.-H., Sasano, H., Ohashi, Y., & Toi, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-06
- Volume
- 376
- Issue
- 22
- Pages
- 2147-2159
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2618058692
- Cited by
- 1,888
- References
- 24
- FWCI
- 34.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.